SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

LIFECORE BIOMEDICAL, INC. \DE\
Date: Sept. 25, 2025 · CIK: 0001005286 · Accession: 0000000000-25-010490

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-290460

Date
September 25, 2025
Author
Division of
Form
UPLOAD
Company
LIFECORE BIOMEDICAL, INC. \DE\

Letter

Re: Lifecore Biomedical, Inc. Registration Statement on Form S-3 Filed September 23, 2025 File No. 333-290460 Dear Tom Salus:

September 25, 2025

Tom Salus Chief Legal and Administration Officer Lifecore Biomedical, Inc. 3515 Lyman Boulevard Chaska, MN 55318

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Daniel Crawford at 202-551-7767 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Ross McAloon, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 September 25, 2025

Tom Salus
Chief Legal and Administration Officer
Lifecore Biomedical, Inc.
3515 Lyman Boulevard
Chaska, MN 55318

 Re: Lifecore Biomedical, Inc.
 Registration Statement on Form S-3
 Filed September 23, 2025
 File No. 333-290460
Dear Tom Salus:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Daniel Crawford at 202-551-7767 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Ross McAloon, Esq.
</TEXT>
</DOCUMENT>